What is Response Genetics Financial Strength?
Response Genetics has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Response Genetics did not have earnings to cover the interest expense.
Response Genetics's debt to revenue ratio for the quarter that ended in Mar. 2015 was 0.72.
As of today, Response Genetics's Altman Z-Score is 0.00.
Competitive Comparison of Response Genetics's Financial Strength
For the Diagnostics & Research subindustry, Response Genetics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Response Genetics's Financial Strength Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Response Genetics's Financial Strength falls into.
Response Genetics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Response Genetics's Interest Expense for the
months ended in Mar. 2015 was $-0.38 Mil. Its Operating Income for the
months ended in Mar. 2015 was $-3.64 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2015 was $10.84 Mil.
Response Genetics's Interest Coverage for the quarter that ended in Mar. 2015 is
| Response Genetics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Response Genetics's Debt to Revenue Ratio for the quarter that ended in Mar. 2015 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Response Genetics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Response Genetics (Response Genetics) Business Description
Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Executives
| Roberto Mignone |
10 percent owner |
C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016 |
| Bridger Management Llc |
10 percent owner |
90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
| Swiftcurrent Offshore Ltd |
10 percent owner |
C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104 |
| David Schreiber |
director |
15 TROTTERS LANE, MONROE CT 06468 |
| Sam Chawla |
director |
1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033 |
| Van Den Broek Richard |
director |
73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830 |
| Kevin Roy Harris |
officer: Vice President and CFO |
345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210 |
| Kirk K Calhoun |
director |
8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
| Michael Serruya |
director |
C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033 |
| Thomas A Bologna |
director, officer: Chief Executive Officer |
4390 US ROUTE ONE, PRINCETON NJ 08540 |
| Marxe Austin W & Greenhouse David M |
10 percent owner |
C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022 |
| Partners Swiftcurrent |
10 percent owner |
90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
| Bridger Capital Llc |
10 percent owner |
90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
| Plc Glaxosmithkline |
10 percent owner |
980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
| Michael A Metzger |
director |
C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451 |
Response Genetics (Response Genetics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGDXQ has been successfully added to your